Legal Battle Over Psilocybin Use for Terminally Ill Patients Intensifies

A significant legal challenge is underway as Dr. Sunil Aggarwal and the Advanced Integrated Medical Science (AIMS) Institute contest the Drug Enforcement Administration’s (DEA) denial of psilocybin for end-of-life care. The case, heard by a federal appeals court, could reshape access to psilocybin, a Schedule I substance, under Right to Try (RTT) laws. These laws allow terminally ill patients to use investigational drugs not yet approved by the FDA. Dr. Aggarwal argues that psilocybin, despite its classification, should be accessible due to its potential therapeutic benefits. The DEA maintains that RTT laws do not override the Controlled Substances Act. Judges questioned the DEA’s rigid interpretation, suggesting the agency could grant exceptions. The outcome of this case could influence the future of psilocybin and similar substances in medical treatments. For more details, see the full article on Benzinga here.